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Myotonic dystrophy is the commonest form of adult muscular dystrophy. 
Myotonic dystrophy 1 and 2 (DM 1 and DM 2) are autosomal dominant inherited 
disorders with unusual multisystem clinical features characterized by myotonia, 
progressive muscle weakness and wasting, cataracts, hypogonadism, frontal 
balding, cardiac conduction defects and diabetes. Severity varies from 
asymptomatic to severely affected phenotypes. DM1 presents with predominantly 
distal weakness whereas DM2 have predominantly proximal weakness.98% of 
patients identified worldwide present with DM1. 
DM 1 is caused by the expansion of an unstable CTG trinucleotide repeat in the 
3' untranslated region of the myotonic dystrophy protein kinase gene on 
chromosome 19ql3.3. DM 2 is linked to the long arm of chromosome 3q21. It is 
caused by a tetranucleotide, CCTG expansion in intron 1 of the zinc finger 
protein 9(ZNF9) gene that interferes with processing of a variety of RNAs. All DM 
mutations can be detected using a combination of the Southern Blot and 
Polymerase Chain reaction (PCR) techniques. 
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Aim: 
This study aims to characterize the clinical spectrum and molecular features of 
myotonic dystrophy patients in KwaZulu - Natal between 1989 and 2005. 
Methodology: 
Patients included in this study were obtained from the database of patients 
diagnosed with Myotonic Dystrophy at the Department of Neurology in KwaZulu-
Natal from 1989 to 2005. Patients were subjected to clinical, radiological and 
neurophysiological assessment. Molecular testing was performed using PCR and 
Southern blot. 
Results: 
Thirty-seven patients with Myotonic Dystrophy were identified. Twenty patients 
consented and were included into the study. Eighty-five percent of patients were 
of Indian descent and the remaining fifteen percent were White. No African 
patients were identified. Sixty-five percent were male and thirty-five percent 
female. Myotonia was clinically present in all patients. Ninety-five percent of 
patients presented with predominantly distal weakness of which 40% 
demonstrated mild weakness, 35% moderate weakness and 25 % severe 
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weakness. No patients were identified with predominantly proximal wasting or 
weakness. Southern blotting demonstrated expanded CTG repeats (DM1) in all 
20 samples analysed. The PCR analysis was unable to demonstrate expanded 
alleles. 
Conclusion: 
This study identified patients presenting with Myotonic dystrophy to the 
Department of Neurology in KwaZulu-Natal and demonstrated that Myotonic 
Dystrophy Type 1 remains the commonest clinical and molecular presentation. In 
addition it substantiated previous research findings wherein no South African of 
African descent was found to be affected by the disease. There have been no 
reported cases of Myotonic Dystrophy in African Black patients presenting to the 
Department of Neurology in Durban, no African Black patients have been 
diagnosed with Myotonic Dystrophy over the past 20 years. However ,the 
predominance of Indians in this study is more likely a reflection of referral bias 
than differing incidence amongst sections of the population. 
PCR analysis cannot detect trinucleotide repeat expansions beyond 200 repeats 
and as a result Southern Blotting remains the gold standard in obtaining a 
molecular diagnosis. A clinical diagnosis is sufficient and molecular confirmation 
is not an absolute requirement. 
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Chapter 1: Introduction 
Myotonic dystrophy is the commonest form of adult muscular dystrophy. 
Myotonic dystrophy 1 and 2 (DM 1 and DM 2) are autosomal dominant inherited 
disorders with unusual multisystem clinical features characterized by myotonia, 
progressive muscle weakness and wasting, cataracts, hypogonadism, frontal 
balding, cardiac conduction defects and diabetes. Severity varies from being 
asymptomatic to severely affected.(1) 
DM 1 is caused by the expansion of an unstable CTG trinucleotide repeat in the 
3' untranslated region of the myotonic dystrophy protein kinase gene in 
chromosome 19ql3.3. (2,3,4) The postulated disease mechanism is thought to be 
the result of a reduction of the DMPK gene product, neighbour gene suppression 
(SIX5) and the processing of RNAs with longer CTG repeats.(4) 
The CTG repeat is polymorphic in the general population. Healthy individuals 
have alleles with repeat lengths ranging from 5 to 35. A repeat length from 35 to 
49 is considered a "premutation" allele. Patients with DM 1 have expansions 
between 50 and several thousand. The size of the repeat is positively correlated 
with disease severity and inversely correlated with age of onset of symptoms. 
DM 1 is characterized by anticipation where affected individuals in succeeding 
generations have an earlier age of onset and a more severe clinical course.(15) 
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Direct analysis of the CTG repeat expansion has a specificity and sensitivity of 
100%. All DM1 mutations can be detected using a combination of the Southern 
Blot and Polymerase Chain reaction (PCR) techniques/1-2-3-465 
PCR is used to identify DM1 repeats of between 5 and 200. Using specifically 
designed synthetic oligonucleotide primers based on the sequences flanking the 
triplet repeats, the unstable region can be easily amplified. If run on a 3,5 % 
metaphor gel along with a size standard, the length of the repeat can be 
accurately determined. Repeats greater than 500 are not reliably amplified by 
PCR. 
Southern blot analysis of DNA digested with one of several restriction 
endonucleases (EcoRl, BamHl, Ncol, Bgl) is the procedure of choice for 
detection of CTG repeats greater than 200. Several probes are available for 
hybridization. Using southern blot analysis, small-expanded alleles can be 
detected, which are seen to co-migrate with the normal allele during agarose gel 
electrophoresis after PCR is performed. This is usually difficult to resolve, hence 
the use of Southern hybridization for these cases. 
These recommendations are based on the new nomenclature and DNA testing 
guidelines for DM1 produced by the International MD Consortium.(6) 
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DM 2 is linked to the long arm of chromosome 3q21. (7) It is caused by a 
tetranucleotide, CCTG expansion in intron 1 of the zinc finger protein 9 (ZNF9) 
gene that interferes with processing of a variety of RNAs.(7,8,9) 
DM 2 closely resembles DM 1 clinically. However, there are important differences 
(9) 
• Absence of a congenital form of DM 2 
• DM 2 is generally a milder disease form with predominant proximal 
weakness and fewer symptoms distally, and less facial and bulbar 
weakness and muscle atrophy. 
• Lack of mental retardation in DM2 
• Central hypersomnolence is seen more commonly with DM 1 
• Anticipation is generally absent in DM 2 
Prior to the discovery of the DM2 gene, 98% of patients with myotonic dystrophy 
demonstrated expanded CTG repeats on chromosome 19.(2,3) Numerous studies 
have been performed focusing on characterizing the molecular and clinical 
spectrum of DM 2 but the frequency with which it occurs in the general 
population or within the DM group is as yet uncertain. The exact incidence of 
DM2 will be easier to determine with increasing testing for the ZNF9 gene. 
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No data has been published regarding the frequency of both forms of DM in 
clinically affected DM individuals in KwaZulu - Natal. 
This study aims to characterize the clinical spectrum and molecular features of 
myotonic dystrophy patients in KwaZulu - Natal between 1989 and 2005. 
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Chapter 2: Myotonic Dystrophy - Literature Review 
2.1 Incidence 
Myotonic dystrophy (DM) is a multisystem autosomal dominant disorder. It is the 
commonest adult muscular dystrophy worldwide with an incidence of 1 in 8000. 
(1) The prevalence of DM1 ranges between 2.1 to 14.3 per 100 000 worldwide. 
DM2 is thought to be equally prevalent. The exact prevalence is unknown in 
South Africa. A previous study by Lotz and Van Der Meyden(10) in 1985 
determined the local prevalence rate for DM in the northern Transvaal as 
14.3/100 OOO.This was a genealogical study performed in the Northern 
Transvaal. Twenty white kindreds with myotonic dystrophy were identified and 
studied: thirteen of Afrikaans, five of English and two of German origin. No cases 
were identified amongst the Black and Indian populations. The local prevalence 
was calculated for the white population of Northern Transvaal and four kindreds 
had a common ancestry.(10) 
2.2 Myotonic Dystrophy Type 1 
2.2.1 Genetics of DM1 
The gene lesion in myotonic dystrophy type 1 is due to a trinucleotide (CTG) 
repeat expansion on chromosome 19ql3.3.(234)The expanded region lies in the 
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regulatory domain of the 3' end. This region is not involved in direct translation 
of the gene product but encodes a serine threonine protein kinase called 
myotonin. (23-4) Complex molecular mechanisms have been postulated at DNA, 
RNA and protein level. At DNA level the expanded CTG repeat may alter the 
structure of chromatin causing dysfunction in neighbouring genes. At RNA level 
the expanded repeat in DM protein kinase (DMPK) mRNA may bind to specific 
proteins and interfere with nuclear function. At protein level the reduced DMPK 
levels may interfere with signal transduction pathways.(2-3A) 
Normal individuals have CTG repeat expansions between 5 and 30 with 5 and 13 
being the most frequent alleles. (3) Individuals affected with DM1 have 
expansions greater than 50. Clinical severity correlates with the size of the gene 
repeat expansion. Individuals with mild signs have a smaller number of repeats 
compared to individuals who have the typical clinical picture of DM1. Congenital 
DM children frequently have the greatest number of repeats. 
Anticipation is a phenomenon occurring in DM1 where the age of onset 
decreases and the severity of disease increases in successive generations. The 
number of CTG repeats is larger in successive generations. This phenomenon 
occurs as a result of instability in the DNA of the DM1 gene leading to an 
increase in the CTG repeats.(1,4) 
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2.2.2 Clinical features of DM1 
Symptoms and signs of DM1 involve several organs. The commonest tissue and 
organs involved are the skeletal muscle, cardiac muscle and smooth muscle. (1) 
The clinical presentation involves various systems. 
2.2.2.1 Muscle weakness 
The muscles frequently involved are the facial muscles, levator palpebrae 
superioris, temporalis muscles, masseters, sternocleidomastoid muscles and the 
distal muscles of the forearm and dorsiflexors of the feet. As the disease 
progresses, weakness can involve the proximal muscles, respiratory muscles and 
bulbar musculature (palatal, pharyngeal and tongue muscles). Extraocular 
muscle involvement may occur. The clinical course is slowly progressive over 
many years and patients may remain stable for prolonged periods of time.(1) 
2.2.2.2 Myotonia 
Myotonia is a delay in relaxation of muscles following contraction. Myotonia is 
thought to result from alteration in function of chloride or sodium channels, 
which are responsible for non-dystrophic myotonia. Myotonia is pronounced in 
the distal muscles of primarily the hands. Affected individuals may be noted to 
have pronounced myotonia of the grip in the early stages often without specific 
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complaints relating to myotonia. As weakness progresses the myotonia tends to 
be less apparent. Percussion of the thenar muscles, forearm extensors and the 
tongue can elicit myotonia.(1) 
2.2.2.3 Involvement of the eye 
Cataracts, retinal degeneration, weakness of the extraocular muscles and 
decreased intraocular pressure are associated with DM1. Cataracts are common 
and occur in 80 % of adults. Cataracts are uncommon in congenital DM. Typical 
iridescent lens opacities and posterior cortical lens opacities are highly specific 
for DM1. The sensitivity is 46.7 % and 50% respectively. The specificity is 100 % 
for both.(11) 
2.2.2.4 Frontal Balding 
Frontal balding is generally more prominent in affected females. 
2.2.2.5 Endocrine abnormalities 
Testicular atrophy occurs in 62 to 86% of male patients. (12) There is impaired 
responsiveness to follicle stimulating hormone with associated hypogonadism.(13) 
In females no ovarian dysfunction is noted. Impairment of adrenal androgens 
and occasionally thyroid dysfunction may occur in patients.(14) Insulin resistance 
is common and may result from an alteration in signaling function of the insulin 
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receptor(12)- Diabetes mellitus occurs in 5% of DM individuals, frequently with 
associated hypersecretion of insulin.(15) 
2.2.2.6 Cardiac Involvement 
Disturbances of cardiac conduction occur frequently in DM. Atrial arrhythmias 
and first-degree heart block are the commonest disturbances. Affected 
individuals may develop complete heart block and require pacemaker treatment. 
Sudden death may occur and is usually due to cardiac arrhythmias. Severe 
congestive cardiac failure is unusual in DM. The cardiac muscle disorder takes 
the form of a dystrophy rather than myotonia and may be responsible for atrial 
and ventricular arrhythmias. (16) Nguyen et al (17) demonstrated fibrosis, fatty 
infiltration and atrophy histopathologically involving the cardiac conduction 
system. Cardiac involvement is an integral part of myotonic dystrophy, affecting 
the infranodal conduction system more significantly than the sinus node and the 
myocardium. Annual electrocardiograph monitoring and early pacemaker therapy 
is effective. 
2.2.2.7 Gastrointestinal disturbances 
Hypomotility and delayed transit time are prominent features. Affected 
individuals commonly present with abdominal cramps, distension and 
constipation. Pseudo - obstruction may occur due to an intestinal myopathy.(18) 
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The frequency of cholelithiasis / cholecystitis is increased due to impaired 
contractility of the gall bladder.(1) 
2.2.2.8 Abnormalities of the peripheral nervous system 
Progression of DM is associated with decrease in the tendon reflexes. A mild 
peripheral neuropathy may also occur. 
2.2.2.9 Abnormalities of the central nervous system 
Changes in personality with associated neuropsychiatric abnormalities such as 
depression may occur in DM. Hypersomnolence with alteration of sleep patterns 
is common in adults with DM. (1) Intellectual impairment occurs commonly. 
Studies (19) have noted a decline in the intelligence quotient as the age of onset 
of signs and symptoms decreased and as the size of the CTG expansion 
increased. One study (20) found that 84% of myotonic dystrophy patients showed 
white matter hyperintense lesions on magnetic resonance imaging, compared 
with 16% of controls. Most of these lesions were bilateral involving all lobes, 
however in 28% of myotonic dystrophy patients the white matter lesions were 
prominent in the temporal poles. Myotonic patients also showed significantly 
more generalized cortical atrophy when compared to the controls. There was no 
relationship between atrophy or white matter hyperintense lesions and age, 
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disease duration, or neuropsychological impairment. (20} However decreased 
cerebral blood flow in the frontal lobe and anterior temporal lobe may play a role 
in the brain manifestations. 
2.2.2.10 Pregnancy related abnormalities 
There is an increased incidence of spontaneous abortion in the first three months 
of gestation.(12) There is an increased incidence of decreased foetal movements, 
polyhydramnios and increased risk of anaesthetic related complications and of 
increased muscle weakness.(21) Myotonia and altered smooth muscle contraction 
power contributes to prolonged labour, increase in instrumental delivery, 
increase in emergency Caesarian sections and post partum haemorrhage. 
Perinatal loss is increased due to congenital DM. Preterm labour is also increased 
if DM affects the foetus. Obstetric complications inversely correlate with age of 
onset of maternal DM.(21) 
2.2.3 Classification of DM1 
Three forms have been classified: 
• Mild DM 
• Classical DM 
• Congenital DM 
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Individuals suffering from a mild form of the disease, present with cataracts and 
mild distal weakness. Myotonia is present but not disabling. Cardiac 
abnormalities may occur. Smooth muscle involvement causing gastrointestinal 
disturbances is not uncommon. In contrast, classical DM individuals have severe 
myotonia with severe muscle weakness. Non-muscular complications are 
increased. The disease has a more rapid course in these patients and lifespan is 
generally decreased. The presence of bulbar and respiratory weakness increases 
the incidence of aspiration pneumonia, hypoventilation and death. Cardiac 
arrhythmias are a frequent cause of sudden death. 
Congenital DM is the most severe form of DM. Affected infants present with 
neonatal hypotonia, motor and mental retardation, facial diplegia, and talipes. 
Respiratory weakness is frequent and often fatal. Cataracts and clinical myotonia 
is usually absent. If these infants survive, they have a static course with 
significant mental retardation and develop complications of adult related DM. 
(1.12) 
Congenital DM is exclusively maternally inherited. Infants are usually born to 
mothers with symptomatic DM. These mothers generally have large expansions 
of CTG repeats. (22) In an affected female, the risk of having a congenitally 
affected child is 3 to 9 %. However the risk increases to 20 to 37 % in the 
subsequent pregnancy if the mother has had one affected child.(23) None of the 
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women with mild DM had a congenially affected child in a study by Koch et al. 
(23) He concluded that the status of the mother during pregnancy had effects on 
the outcome of the child and that only mothers with multisystem symptoms are 
at risk of having a congenitally affected child.(23) 
2.2.4 Investigations of DM1 
Additional investigations can be performed. 
• Serum creatinine kinase may be elevated 
• Electromyography demonstrates myotonic potentials and myopathic 
features. Myotonic potentials appear as repetitive bursts of potentials 
which wax and wane in amplitude and frequency. 
• Muscle biopsy is usually non-specific. It demonstrates central nuclei, 
sarcoplasmic masses and ring fibers. Necrosis, regeneration and increase 
of collagen are not severe. Seventy percent hypotrophy of Type 1 muscle 
fibers is observed. Markedly atrophic fibers are less common.(1,24) Repeat 
expansions can be detected in skeletal muscle samples.(24) 
2.2.5 Management of DM1 
Treatment is supportive. Physiotherapy, splinting and lightweight ankle orthoses 
are used for muscle weakness and foot drop. In severe weakness, walking aids 
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or wheelchairs are required. The myotonia may be treated with drugs such as 
phenytoin or quinine. Individuals with severe ptosis may require lid-elevating 
crutches. Lid surgery is usually not indicated. Annual electrocardiographs are 
required to monitor for arrhythmias and heart block. A PR interval greater than 
0.2 seconds indicates an increase risk for severe heart block. If severe, a 
pacemaker may be inserted. Annual ophthalmology visits are required to detect 
cataracts. If present, surgery is well tolerated under local anaesthetic. 
Gastrointestinal symptoms may be treated conservatively. Patients need to avoid 
high fat foods and maintain bulk in their diet with adequate fluid intake. 
Hypersomnolence may be treated with methylphenidate or modafinil. Depression 
may be treated with antidepressants. Respiratory weakness can be treated with 
breathing exercises, postural drainage and nocturnal respiratory support. 
Patients are at an increased risk of developing complications from anaesthetic 
agents such as thiopentone. DM patients must be well informed and educated 
about their condition. 
2.2.6 Genetic counseling in DM1 
In a symptomatic individual, molecular testing for DM is part of a diagnostic 
evaluation. In genetic counseling, an experienced genetic counselor educates 
and counsels the patient about the implications of the testing. Patients require 
emotional support and assistance in dealing with the results. Asymptomatic 
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family members may request molecular testing to determine their status. Genetic 
counseling is an essential part of the testing process. Testing is not performed in 
unaffected children less than eighteen years of age. Prenatal genetic testing may 
be performed to assess if the foetus is affected. In a complicated pregnancy the 
presence of a positive test with a large repeat expansion indicates that the 
foetus is likely to have severe congenital DM. This information can be helpful in 
preparing for the birth and delivery and some parents may consider termination 
of pregnancy. However the above raises ethical issues and prenatal testing 
should be thoroughly discussed with the patient. 
2.3 Myotonic dystrophy Type 2 
2.3.1 Genetics of DM2 
In initial reports (3) the clinical and genetic diagnosis of DM were almost 
concordant with more than 98 % of affected individuals demonstrating the DM1 
gene defect. Subsequently, numerous case reports identified individuals with 
autosomal dominant myotonia associated with systemic features of DM but with 
the absence of the DM1 expansion. Clinical differences were observed consisting 
of mainly proximal weakness, milder disease and the absence of a congenital 
form. As a result the existence of a second locus was considered.(25) 
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Thornton et al (26) described patients who presented with multisystem disease 
associated with myotonia and weakness. The clinical assessment of DM1 was 
considered however no CTG repeat expansions were detected in the DM1 locus. 
They reported the lack of anticipation, weakness primarily in the proximal 
distribution and limb muscles that were large or hypertrophied.(26) 
Ricker et al (7) described 17 families with similar findings and proposed that 
proximal myotonic myopathy was a multisystem disorder similar but distinct from 
DM. However in 1998, the second DM locus was mapped to chromosome 3q. 
(7)The DM2 mutation was identified as a CCTG expansion in intron 1 of ZNF9 on 
chromosome 3q21 and was present in the families previously described with 
proximal myotonic myopathy. (89) The pathophysiological mechanism is thought 
to be an accumulation of expansions as intranuclear RNA foci, which cause global 
disruptions in RNA splicing and cellular metabolism. The alteration of splicing of 
insulin receptors and chloride channel transcripts may cause insulin insensitivity 
and myotonia respectively.(9) 
2.3.2 Clinical features of DM2 
The clinical features were defined by Day et al in 2003. (9) One hundred and 
thirty three families of European descent were identified. Clinical features were 
similar to DM1 with some exceptions. Common features included progressive 
weakness, myotonia, cataracts, cardiac involvement, testicular atrophy, and 
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insulin insensitivity. Fluctuating or episodic muscle pain was common in patients 
greater than 50 years of age. The characteristic pattern of weakness in DM2 
involved the neck flexors, elbow extensors, thumb and deep finger flexors, hip 
flexors and hip extensors. Dorsiflexion weakness and facial weakness was less 
common when compared to DM1. Thirty percent of patients who were greater 
than 50 years of age, presented with hip girdle weakness. Bulbar weakness was 
uncommon and muscle atrophy was less pronounced. These patients lacked 
mental retardation and had a decreased incidence of central hypersomnolence. 
DM2 patients did not demonstrate a congenital form and anticipation was not a 
prominent feature.(9,28) 
2.3.3 Investigations of DM2 
• Creatinine kinase may be elevated as in DM1 
• Electrocardiography may detect arrhythmias 
• Electromyography demonstrates typical myotonia and myopathic features 
• Muscle biopsy is similar to DM1 with centrally located nuclei, angulated 
atrophic fibers and severely atrophic fibers with pyknotic nuclear clumps. 
Occasional necrosis, fibrosis and adipose deposition is seen.(9) Preferential 
type 2 fiber atrophy and the absence of type 1 fiber atrophy distinguishes 
DM2 from DM1.(29) Higher frequency of nuclear clump fibers are also seen 
in DM2.(29) 
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2.3.4 Management of DM2 
The management of DM2 is similar to DM1. Treatment is supportive and 
symptomatic. Annual ophthalmology visits and electrocardiography are required 
to detect cataracts and cardiac arrhythmias respectively. 
2.3.5 Genetic Counseling in DM2 
As in DM1 all individuals require genetic counseling prior to molecular testing. 
Prenatal testing is not required in view of the absence of a congenital form. 
2.4 Myotonic dystrophy Type 3 
In 2004, Hannequin et al (30) described a new disease entity of proximal 
weakness, clinical myotonia, early bilateral DM1 type cataracts and early onset 
dementia in individuals from three generations who underwent detailed 
neurological examination and linkage analysis. 
These patients developed slow progressive weakness associated with muscle 
pain, myotonia, cataracts and mildly increased creatinine kinase. In later stages 
they developed severe weakness with severe frontotemporal dementia. 
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Molecular analysis excluded DM1 and DM2. The age of onset was earlier in 
subsequent generations suggestive of anticipation. Muscle biopsy showed non-
specific myopathic features with type 1 and type 2 fibers being equally atrophied, 
which differs from DM1 and DM2. 
Neuropsychological testing, frontal hypoperfusion on single-photon emission 
computed tomography and neuropathological features of frontotemporal 
spongiosis, neuronal loss and neuronal and glial tau inclusions were consistent 
with frontotemporal dementia. 
Magnetic resonance imaging demonstrated cortical atrophy without white matter 
lesions. Genome wide screen analysis strongly suggested a locus at 15q21-24 
under a dominant model. This disease entity has been proposed as myotonic 
dystrophy type 3 (DM3).(30) 
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Chapter 3:Molecular Diagnosis of Myotonic Dystrophy Type 1 
Myotonic dystrophy demonstrates an autosomal dominant pattern of inheritance. 
(L4) Phenotypic variability, multisystem involvement and anticipation are 
important aspects evident in this disorder. Anticipation is an increase in severity 
of symptoms and a reduction in age of onset that is observed during 
transmission of the gene within families. (1-2-3A5> 
Myotonic dystrophy type 1 (DM1) has been mapped to chromosome 19ql3.2-
13.3 by genetic linkage analysis.(2-3-4-31) in DM1 individuals, a highly polymorphic 
CTG repeat was identified and found to be unstable with an increased number of 
repeats.(234) The mutational mechanism leading to myotonic dystrophy was 
attributed to a triplet amplification of the CTG repeat residing in the 3' 
untranslated portion of the protein kinase gene and in the promoter region of 
the immediately adjacent homeodomain gene, SIX5 ,(2-3-4-8) Suggested 
mechanisms for the cause of the clinical phenotype includes (8): 
a) Haploinsufficiency of the dystrophia myotonica protein kinase protein. 
b) Altered expression of neighbouring genes, for example SIX5. 
c) Pathogenic effects of the CUG expansion in RNA which accumulates in 
nuclei and disrupts cellular function. 
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The extent of the increase in the allele size showed a correlation with increased 
severity and earlier age of onset.(4) An increase in the number of CTG repeats 
results in an increase in the size of the polymerase chain reaction products 
(PCR). Polymerase chain reaction analysis of severely affected individuals reveals 
only a single band in the normal range.(4) The expanded allele cannot be easily 
visualized by PCR assay in these patients.(6) 
Normal individuals have 5-37 CTG repeats located at the myotonic dystrophy 
locus.(4,6) The most frequent allele in the general population is 5 repeats (35%), 
followed by 11, 12 and 13 repeats (50%). (23'32) Greater than 30 repeats are rare 
(less than 2%). (32) Individuals affected with myotonic dystrophy have a 
minimum of 50 repeats, which is almost double the normal population.(4,6)It is 
postulated that doubling or tripling in repeat numbers may be the ancestral 
event that predisposes an allele at the myotonic dystrophy locus to expand into 
an allele associated with disease expression.(4,6) 
Stable transmissions of a minimal CTG repeat expansion may occur by individuals 
with mild manifestations allowing persistence of the myotonic dystrophy 
mutation in the population.(33)Stability of the CTG repeat in myotonic dystrophy 
appears to be a function of size. Once the size of the allele is greater than 80 
CTG repeats, stability is unlikely, resulting in anticipation.(33) Stable transmissions 
have been well documented in individuals with 50 to 80 CTG repeats.(33) 
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Asymptomatic / minimally affected DM individuals have small expansions known 
as protomutations (50 to 80). These are inherited in a stable form if transmitted 
by a female.(32) However if transmitted through male germline they result in a 
large increase resulting in symptomatic myotonic dystrophy.(32)Repeat sizes of 38 
to 50 are called pre mutations and form the pool from which protomutations and 
full mutations arise.(32) 
The incidence of DM1 is constant in the population despite anticipation and the 
low reproductive fitness in affected individuals. Some mechanism exists to 
maintain the population incidence of DM1.A common haplotype has been found 
in European and Asian populations indicating a founder effect.(32) Martorell et al 
(32) demonstrated mutations involving alleles in the normal range (4 to 37). All 
were expansions and the majority paternally transmitted. All were greater than 
25 repeats in length.(32) These data supported the hypothesis that multiple 
mutations of alleles within the normal range lead to a gradual increase in CTG 
repeat lengths eventually generating new premutation size alleles.(32) 
Martorell et al ( 32 ) also observed the presence of premutations of 38 to 50 repeats 
in individuals with no clinical symptoms of myotonic dystrophy. Of the 
transmissions observed, all demonstrated an increase length in the next 
generation suggesting an increase risk of developing DM1 in future generations. 
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Paternal transmissions demonstrated larger repeats reflecting male bias in the 
generation of new DM1 alleles from premutations and protomutations.(32) 
Congenital myotonic dystrophy shows exclusively maternal inheritance and large 
repeat sizes of greater than 2000.(4) In congenital myotonic dystrophy , the 
paternal allele was shown to be inherited unaltered whilst the maternal allele 
was unstable suggesting that the triplet repeat becomes unstable during 
germline meiosis once the repeat number exceeds 50.(2) With the exception of 
congenital DM , male carriers are more likely than female carriers to give rise to 
offspring with large expansions.(33) 
The molecular diagnosis of DM1 is based on the guidelines of the International 
Myotonic Dystrophy consortium. (6) The presence of 35 to 49 repeats is classified 
as premutation alleles and greater than 50 as symptomatic DM. The presence of 
50 to 150 repeats is usually associated with mild DM, 100 to 1000 repeats with 
classic DM and greater than 2000 being found in congenital DM. 
The combined southern blot and polymerase chain reaction tests can detect all 
DM1 mutations without false positives. PCR amplification of the CTG repeat 
region of genomic DNA revealed that unaffected alleles are readily amplified, 
while the mutant alleles are not usually visualized.(3) Expanded alleles have a 
blurred appearance on Southern Blots.(3) 
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Southern blot analysis of genomic DNA digested by restriction endonucleases is 
the procedure of choice for detection of repeats greater than 100. However small 
alleles may co migrate with normal alleles during gel electrophoresis making 
diagnosis difficult. PCR is then used to detect repeats less than 200 in size. Using 
synthetic oligonucleotide primers based on sequences flanking the triplet repeat, 
the unstable repeat is amplified. If the PCR product is run on 3,5% metaphor gel 






FIGURE 3.1. EXAMPLE OF A PCR ANALYSIS OF A FAMILY WITH A CHILD 
WITH MYOTONIC DYSTROPHY 
In this case, the parents were asymptomatic but the father (F) had an allele in 
the intermediate range (not fully expanded allele). Mother (M) shows two normal 
alleles (black arrows) and the father one pre-expanded allele (white arrow). The 
child (C) has one normal allele from mother and does not have any allele from 
the father and is symptomatic i.e. the pre-expanded allele has turned into a full 
expansion in the affected child and is not amplified in the PCR analysis. 
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FIGURE 3. 2. SOUTHERN BLOT DEMONSTRATING EXPANSION IN THE 
FOUR LANES WITH A NEGATIVE CONTROL IN THE FIFTH LANE. 
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Chapter 4:Molecular Diagnosis of Myotonic Dystrophy Type 2 
Ranum et al (7) reported the mapping of a second myotonic dystrophy locus in 
1998 after identifying a large family with clinical similarity to DM1 but the 
absence of chromosome 19 CTG expansions. Linkage analysis was used to 
determine the disease locus. Based on an autosomal dominant inheritance 
model, the analysis excluded chromosome 19 as a locus. In addition other loci 
known to be associated with myotonia were excluded. These were the sodium 
channel gene (SCN 4A) on chromosome 17q and the chloride channel gene 
(CICN1) on chromosome 7q. Further genetic mapping identified a 10-cM region 
of chromosome 3q as the second locus.(7) 
Using positional cloning, Liquori et a l ( 7 ) identified the myotonic dystrophy type 2 
(DM2) mutation as a CCTG expansion in intron 1 of ZNF9 on chromosome 3q21. 
ZNF9 is referred to as the cellular nucleic acid binding protein gene and is 
thought to be a RNA binding protein. The accumulation of expansions as RNA 
foci may cause global disruptions in RNA splicing and cellular metabolism. No 
congenital form was seen.(7) 
Conventional Southern blot techniques have proven unsatisfactory for DM2 due 
to the extremely large size of expansions.(34) Overall sensitivity of southern blot is 
70 to 80%.(34) 
33 
Day et a l ( 9 ) developed a repeat assay, which amplifies the genomic DM2 region 
containing the repeat expansion followed by southern blot analysis of the PCR 
products probed with an internal probe. The DM2 repeat assay and repeat -
primed PCR has been reported to overcome the sensitivity problem.(19) Day et al 
(9) demonstrated a sensitivity of 99% for detecting expansions with the repeat 
assay when compared to 80% detection with Southern blot. 
Sallinen et al recently described in situ hybridization to detect both the genomic 
expansion and the mutant transcripts in muscle biopsy sections. Flourescence in 
situ hybridization on extended DNA fibers was used to directly visualize the DM2 
mutation and estimate expansion size.(34) Chromogenic in situ hybridization may 
provide a convenient and reliable method for diagnosis whilst fluorescence in situ 
hybridization is useful as a research tool. 
Currently the proposed three step molecular diagnostic procedure includes(34): 
a) PCR based allele sizing for the exclusion of DM2 in individuals with two 
normal amplifiable alleles. 
b) Southern Blot analysis 
c) Repeat assay 
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Chapter 5: Research methodology 
5.1 Aim 
The main objective of this study is to describe the clinical and molecular 
spectrum of myotonic dystrophy patients in KwaZulu - Natal. 
5.2 Patient identification 
Patients included in this study were identified from the database of patients 
diagnosed with Myotonic Dystrophy at the Department of Neurology in KwaZulu -
Natal from 1989 to 2005. The research and ethics committee of the University 
of KwaZulu-Natal approved the study. 
5.3 Data Collection Method 
All patients were informed about the study (appendix 1). Only those who gave 
informed consent were enrolled (appendix 2). The study was performed at Inkosi 
Albert Luthuli Central Hospital (IALCH), the major tertiary health care referral 
hospital of the province of KwaZulu-Natal. The study involved the collection of 
both prospective and retrospective data. Data was collected on a Myotonic 
Dystrophy Data sheet (appendix 3). 
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Data collected included: 
5.3.1. Epidemiological data 
5.3.1.1 Age 
5.3.1.2 Gender 
5.3.1.3 Ethnic group. 
5.3.2. Clinical data 
5.3.1.1 History: age of onset of symptoms and associated family 
history 
5.3.1.2 General examination: including Blood pressure, pulse, 
frontal balding and testicular atrophy 
5.3.1.3 Neurological examination: mini mental state 
examination, associated hypersomnolence, cranial nerve 
examination including the presence of cataracts, distribution 
of wasting, presence of myotonia in forearm extensor 
groups and thenar muscles, motor strength determined 
using the standard scale of 0 -5, reflexes (quantified 0 - 4 ) 
(0 = absent 1 = depressed 2 = normal 3= brisk 4 = clonic), 
sensation, co ordination and gait (ambulant, walks with aid, 
unable to walk). 
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5.3.3. Haematological data 
• Full blood count 
5.3. 4. Biochemical data 
• Urea and electrolytes 
• Liver function tests 
• Glucose, calcium, phosphate, magnesium and cholesterol 
• Creatinine Kinase 
5.3.5. Radiographic data 
• Chest x ray 
5.3.6. Electrocardiography data 
5.3.7. Nerve conduction studies and electromyography data 
• Looking for an associated neuropathy 
• Myopathic features and myotonic discharges. 
5.3.8. Molecular diagnostic data 
• Polymerase chain reaction and Southern Blot analysis. 
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5.4. Methodology for molecular diagnostic testing 
Consent for DNA analysis was obtained from each patient attending the 
neurology or neuromuscular clinic. Blood samples were collected in EDTA tubes. 
DNA extractions were performed using conventional procedures and PCR analysis 
of the patients DNA was performed at the Neuroscience Laboratory, University of 
KwaZulu - Natal. Samples were sent to the Department of Genetic Medicine, Sir 
Ganga Ram Hospital, Rajinder Nagar, New Delhi for further analysis by PCR and 
southern hybridization. 
The following primers were utilized: 
• The DM1 CTG repeat expansion was amplified using the 
primers for the DM1 locus. Primer sequences were 
as follows: 
o 101F: 5' CTT CCC AGG CCT GCA GTT TGC CCA TC 3' 
o 102R: 5' GAA CGG GGC TCG AAG GGT CCT TGT 
AGC3' 
• The DM2 repeat region was amplified from the genomic DNA 
using the following primer sequences: 
o CL3N58-D F (5' GCC TAG GGG A CAA AGT GAG A 
30 
o CL3N58-D R (5' GGC CTT ATA ACC ATG CAA ATG 
3') 
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5.4.1 PCR analysis at University of KwaZulu - Natal Neuroscience 
Laboratory 
PCR analysis in University of KwaZulu - Natal Neuroscience Laboratory was 
performed as follows: 
• Optimised PCR procedures using the primers specific for 
DM1 were performed on all patient samples. 
• A PCR assay was optimized using primers specific for DM2, 
and all patient's negative for the DM1 expansion were 
subjected to the PCR assay for DM2. 
• PCR products were electrophoresed on a 2% agarose gel 
and analysed using the GelDoc software from Biorad. 
• The PCR products were subsequently purified using the 
HighPure kit from Roche. 
• The purified products were subjected to DNA sequence 
analysis using the 3100 Genetic Analyser. 
• The results were analysed using the Biotools DNA sequence 
analysis software. 
• Those patients' samples found not to have a DM1 or DM2 
duplication using the PCR assays were subjected to Southern 
hybridization using specifically designed probes. 
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5.4.2. DNA analysis at Department of Genetic Medicine, Sir Ganga Ram 
Hospital 
DNA analysis at Department of Genetic Medicine, Sir Ganga Ram Hospital was 
done using the methods described in Current Protocols in Human Genetics. (1J) 
5.4.2.1 Materials 
. 10 mM dNTP mix 
• 10 x PCR amplification buffer with 15mM MgCI2 
• 10 ng/ul PCR primer la ( 5 ' GG AGG ATG GAA CAC GGA CGG 3 * )or 
primer 1 b ( 5 ' CAG AGC AGG GCG TCA TGC ACA 3x) 
• 10 ng/ul PCR primer 2 : ( 5 ' GAA GGG TCC TTG TAG CCG GGA A31) 
• 5 U/ul Taq DNA polymerase 
• DNA sample: 50ng of purified genomic DNA 
• Mineral oil 
• 10 x gel loading buffer 
• 1.8 % agarose gel 
• 1 x TBE buffer 
• 10 mg/ml ethidium bromide 
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5.4.2.2. Preparation of PCR reaction 
0,5 ml PCR tubes are labeled. One for each DNA sample , plus positive and 
negative controls. DNA with a known large DM expansion should be used as a 
positive control for PCR and a sample with water in place of the DNA should be 
used as a negative control. For each sample a PCR reaction mix is prepared 
using: 
. 4 pi 10 mM dNTP (200 pM) 
• 2.5 uL 10 x PCR amplification buffer with 15 mM MgCI2 
• 5 pi 10 ng / pi PCR primer 1 
• 5 pi 10 ng/pl PCR primer 2 
• 7.25 pi autoclaved water 
• 0.25 pi 5 U/pl Taq DNA polymerase 
• PCR primer product is 64 base pairs larger when using the primer 
lbcompared to primer la. 
• An aliquot of 1 pi DNA sample is added into the tube using a separate 
DNA pipette. The reactions are covered with mineral oil. 
5.4.2.2.1. Preparation of PCR reaction- Electrophoresis of PCR products 
• 73 ml of a 1,8% agarose gel in 1 x TBE buffer is prepared. 
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• 10 mg/ml of ethidium bromide is added to 0.5 ug/ml and the gel is 
poured in a 15 x 10 cm tray with a 0.8 mm thick comb. 
• 10 x gel loading dye is added to 5 pi of PCR product to achieve a final 
concentration. 
• This is applied to the gel. 
• One lane of appropriate molecular sized markers is applied. 
• The gel is electrophoresed at 80 V, 90 mA in a 1 x TBE buffer that does 
not contain ethidium bromide. 
• When the bromophenol blue dye front has traveled 3,5 cm from the wells 
, the gel is photographed. 
• The normal allele is usually within the ethidium bromide front. 
• The DM mutant alleles are usually heterogenous in size and are not 
typically visualized by ethidium bromide staining. 
• Electrophoresis must be stopped when the bromphenol blue dye front has 
traveled 5.5 cm from the wells and the xylene cyanol dye front has 
traveled 2cm. 
5.4.2.2.2. Preparation of PCR reaction -Transfer of PCR products to nylon 
membrane 
The CTG-PCR product can be transferred overnight by capillary transfer to a 
positively charged nylon membrane. DNA can be fixed to the membrane with 
baking or ultraviolet cross-linking. 
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5.4.2.2.3. Preparation of PCR reaction - Hybridize the membrane 
• The membrane is pre-hybridized in a pre-hybridization /hybridization 
buffer for at least 1 hour and 30 minutes to 12 hours at 50° C. 
• The buffer is then discarded. 
• 20 pi alkaline Phosphatase - conjugated (CTG)io 
• Oligonucleotide is added to 20 ml fresh pre-hybridization / hybridization 
buffer and is hybridized to membrane for lhour and 30 minutes to 2 
hours at 50° C. 
• Wash buffers 1 and 2 are pre-warmed to 50° C. 
• The membrane is removed from the pre-hybridization / hybridization 
buffer and excess liquid is drained. 
• The membrane is washed using the following regimen: 
• Wash bufferl - two times, 5 minutes each at 50° C 
• Wash buffer 2 - two times, 5 minutes each at 50° C 
• Wash buffer 3 - one time, 5 minutes at room temperature 
5.4.2.2.4. Preparation of PCR reaction- Develop Signal 
• The membrane is placed on a clean surface. 
• Lumi- Phos 530 substrate solution is sprayed sparingly from a height of 12 
to 18 inches. 
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• The membrane is covered completely and evenly. 
• The membrane is wrapped in plastic wrap or acetate protective sheets. 
• The edges are sealed well to prevent excess Lumi - Phos 530 from 
leaching out and producing artifacts. 
• The blot is then exposed to Kodak X- AR autoradiographic film 3 hours to 
overnight at 37° C and viewed. 
• Myotonic Dystrophy expansions appear as diffuse smears. 
5.5 Statistical Analysis 
Data were captured in Microsoft excel and exported into SPSS version 11.5 (SPSS 
inc. Chicago, Illinois, USA) for statistical analysis and simplifications. Simple one-
way frequencies, bar charts and Pie charts were used to describe categorical 
variables. Quantitative variables were described using descriptive statistics e.g. 
means. 
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Chapter 6: Results 
6.1. Introduction 
This chapter reports on the results of the study. Twenty-five patients were 
identified from previous referrals to the neurology department. A further twelve 
relatives were identified from their records. From the thirty-seven individuals 
identified, twenty were included in the study. The remaining seventeen patients 
had been diagnosed clinically with myotonic dystrophy type 1 but were not 
included as they were either deceased (5), refused consent (5) or could not be 
contacted (7). Thirteen of these patients were first-degree relatives of patients 
included into the study. Clinical data, follow up visits and molecular results were 
available in the 20 patients included in the study. 
6.2. Findings 
6.2.1. Demographic Information 
6.2.1.1 Race 
From the following pie chart it can be seen that 85 % of patients were of Indian 
descent and the remaining 15% were White. No African patients were identified 
in both the included and excluded patients. 
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FIGURE 6.1. PIE CHART DEPICTING BREAKDOWN OF RACE 





Results showed that 65% were male and 35% female 
FIGURE 6.2. PIE CHART DEPICTING BREAKDOWN OF GENDER 
iOMale 
' • Female • ! 
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6.2.1.3 Gender and Race 
The following chart highlights the breakdown in terms of both race and gender. 












Table 6.1. Displays the age demographics. In the majority (65%) the age of 
onset of clinical symptoms was below the age of 40 years. The mean age of 
onset of symptoms for the sample was 31.35 years. The average age of the 
sample was 40.80 years with a range of 17 to 65 years. 
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TABLE 6.1. AGE DEMOGRAPHICS OF PATIENTS 
Mean 
Range 
Mean age of onset of symptoms 




FIGURE 6.4. BAR CHART PRESENTING BREAKDOWN OF THE AGE OF 




































Age of Onset 
• greater than 40 
• less than 40 
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6.2.1.5 Family History 
Twenty Five percent had no family history of note. Of the remaining 75%, 
positive parental history was noted in 30%, 65% in siblings and 10% in 
offspring. 
FIGURE 6.5. BAR CHART DEPICTING BREAKDOWN OF FAMILY 
HISTORY 
Number of 
responses • No family history 




Four patients were part of a large family and their pedigree analysis 
demonstrated an autosomal dominant pattern of inheritance. 
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The four affected individuals who were not included into the study were 
diagnosed on history. They had been evaluated elsewhere and molecular studies 
reportedly confirmed their diagnosis. The following Family tree highlights this: 
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6.2.2. Clinical findings 
6.2.2.1. Blood Pressure and Pulse 
No abnormalities were noted in the vital signs. One patient was on treatment for 
hypertension. 















• Blood Pressure 
Status 
6.2.2.2. Frontal Balding 
Frontal balding was present in 80% of patients. 
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FIGURE 6.8. PIE CHART SHOWING PRESENCE OF FRONTAL BALDING 
6.2.2.3. Testicular atrophy 
Testicular atrophy was present in 38% of patients. 





6.2.2.4. Mini mental state examination 
Fifty five percent of the sample demonstrated a normal MMSE of 30 whilst 25% 
demonstrated mild cognitive impairment of between 26-29 and 20% moderate 
impairment (20-25). 
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6.2.2.5. Hypersomnolence 
Symptoms of hypersomnolence were found in 30% with 5% requiring treatment 
with methylphenidate. 
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FIGURE 6.11. PIE CHART DEPICTING PREVALENCE OF 
HYPERSOMNOLENCE 
6.2.2.6. Cataracts 
Forty percent of the sample presented with either unilateral or bilateral cataracts 
at bedside ophthalmoscopy. 
6.2.2.7. Levator palapebrae superioris and extraocular muscle weakness 
Ptosis was found in 70% with 15% having additional ophthalmoplegia. 
6.2.2.8. Temporal, masseter and facial muscle wasting and weakness 
Temporal muscle wasting was found in 75% of patients. Masseter muscle 
wasting was found in 65% with 20% demonstrating masseter weakness. Facial 
wasting was seen in 90% and 95% had demonstrable facial weakness. 
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The following Bar chart highlights the Clinical Findings of Cataracts, Ptosis, 
Ophthalmoplegia, Temporal Wasting , Masseter Wasting, Weakness, Facial 
Wasting and Facial Weakness. 
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7 Yes Prevalence 
6.2.2.9 Auditory examination 
Only 5 % (1 patient) of the sample was found to have hearing impairment on 
clinical examination. The patient demonstrated bilateral sensori-neural hearing 
loss. 
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6.2.2.10. Bulbar muscle involvement 









Dysphagia was uncommon (20%). Dysarthria / dysphonia was present in 50 % 
of the patients. 
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6.2.2.11 Sternocleidomastoid Involvement 
Sternocleidomastoid wasting and weakness was seen in 80% of patients. 



















, - j f f » - i ' 







6.2.2.12 Distribution and severity of wasting in limbs 
Forty five percent of patients presented with predominantly distal wasting 
whereas 40% had wasting of both proximal and distal muscle groups. No 
patients were identified with predominantly proximal wasting. Wasting was 
evident in both upper and lower limbs in 70% of patients. 40% had evidence of 
moderate wasting with 20% demonstrating severe wasting. 
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Myotonia was clinically evident in all patients. All patients demonstrated 
percussion myotonia in thenar muscles with an additional 65% in the forearm 
extensors. 
FIGURE 6.17. BAR CHART DEPICTING PREVALENCE OF MYOTONIA 






















6.2.2.14 Distribution and severity of weakness 
Ninety five percent of patients presented with predominantly distal weakness of 
which 40% demonstrated mild weakness (power grading of greater than 4), 
35% moderate weakness (power grading of 4 and 4 -) and 25 % severe 
weakness, (power grading of 3 or less). 






























6.2.2.15 Tendon reflexes 
Reflexes were depressed in 10% and absent in 70%. 
FIGURE 6.19. PIE CHART HIGHLIGHTING TENDON REFLEXES 
6.2.2.16. Sensory examination 
Sensory examination was normal in 95 % with one patient demonstrating mild 
glove and stocking sensory loss. 
6.2.2.17. Co ordination 
Co ordination was preserved in all patients. 
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FIGURE 6.20. BAR CHART HIGHLIGHTING SENSORY EXAMINATION 
AND CO ORDINATION 




Seventy percent of patients remained ambulant while 20% required a walking 
aid and the remaining 10% were wheelchair bound. 
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FIGURE 6.21. PIE CHART HIGHLIGHTING EXAMINATION OF GAIT 
D Ambulant 
• Walks with aid 
O Unable to walk 
6.2.3. Laboratory investigations 
Basic blood investigations such as full blood count, renal function, liver function 
and electrolytes were all normal. 
• Elevated cholesterol was noted in 30%. 
• One patient was on treatment for hypothyroidism. 
• Three (15%) patients were being treated for diabetes mellitus type 2. 
• Creatinine Kinase was mildly elevated in 50% .The highest level obtained 
was 899. Twenty percent had normal values. Thirty percent had no 
available creatinine kinase results. 
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6.2.4. Radiographic investigations 
The chest radiograph was normal in 80% with the remaining 20% having no 
available CXR. 
6.2.5. Electrocardiography 
Electrocardiography was performed in 75% of patients. 55% were in sinus 
rhythm. Three patients (15%) had evidence of left bundle branch block. One 
patient (5%) had a right bundle branch block. PR interval was not measured in 
this study. 
6.2.6. Nerve conduction studies 
Nerve conduction studies were obtained in 60% of patients and were normal in 
55%. One patient demonstrated an abnormality. Unilateral studies were 
performed. The upper limb motor and sensory studies were normal. The lower 
limb study demonstrated a decrease in the amplitude (60% of the lower limit of 
normal) of the compound muscle action potential on stimulation of the common 
peroneal nerve when recording from the extensor digitorum brevis. The latency 
and conduction velocity were normal. The sural sensory potential was normal. 
6.2. 7. Electromyography 
Electromyography was performed in 85 % of patients with all demonstrating 
typical myotonic changes while 40% had evidence of myopathic findings as well. 
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6.2.8. Management 
All patients were managed supportively with physiotherapy and occupational 
therapy. 
6.2.9. Follow up 
At the end of the study date two patients (10%) had demised and one (5%) was 
lost to follow up. The cause of death in the two patients was unknown. The 
remaining patients were followed up either telephonically or with a recent visit to 
our clinic. 
6.2.10 Molecular Analysis 
The PCR analysis performed at the Sir Ganga Ram Hospital Genetics Department 
and the University of KwaZulu Natal Laboratory , was unable to demonstrate 
expanded alleles in all 20 samples. PCR analysis is sensitive for determining 
trinucletide repeat expansions of less than 200 in size. 
Southern blotting performed at Sir Ganga Ram Hospital demonstrated expanded 
CTG repeats in all 20 samples. Expanded trinucleotide repeats that are only 
detected on southern blot testing imply trinucleotide repeat sequence expansions 
of greater than 200 in size. 
The evaluation of southern blotting performed at Sir Ganga Ram Hospital could 
not quantify the exact number of trinucleotide repeat expansions. 
However the findings were sufficient to indicate that all patients demonstrated 
trinucleotide repeat expansions beyond 200. 
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FIGURE 6.22. EXAMPLE OF A SILVER STAINED PAGE PCR PICTURE OF 
SAMPLES ALONGSIDE A MARKER ( ARROW) 
1 2 3 4 5 6 7 8 9 10 11 12 13 
The above example demonstrates how PCR samples are compared to a marker 
to determine the size of the alleles. Lanes 1 to 12 demonstrate PCR products 
which are normal. Lane 13 contains markers representing different size of alleles. 
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FIGURE 6.23. PCR OF PATIENTS 1 TO 10. SILVER STAINED PAGE 
PICTURE SHOWING PRESENCE OF ONLY ONE ALLELE, WHICH IS IN 
THE NORMAL RANGE 
8 10 
Lanes 1 to 10 demonstrates PCR product of 10 patients showing 1 allele in the 
normal range. 
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FIGURE 6. 24. PCR OF PATIENTS 11 TO 20. SILVER STAINED PAGE 
PICTURE SHOWING PRESENCE OF ALLELE IN THE NORMAL RANGE. 
11 12 13 14 15 16 17 18 19 20 
Lanes 11 to 20 demonstrates PCR product of 10 patients showing 1 allele in the 
normal range 
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FIGURE 6.25. SOUTHERN BLOT DEMONSTRATING A NEGATIVE 
CONTROL IN LANE 3 AND POSITIVE CONTROLS IN LANES 1 AND 2. 
SAMPLES OF PATIENTS 1 TO 10 IN LANES 4 TO 13 DEMONSTRATE 
EXPANSION. 
1 2 3 4 5 6 7 8 9 10 11 12 13 
4 * 
- t * x * 
*l m 
ft 
Attn I I *H-0$ 
V -*2% 
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FIGURE 6.26. SOUTHERN BLOT DEMONSTRATING NEGATIVE CONTROL 
IN LANES 1,2 AND 3. SAMPLES OF PATIENTS 11-20 DEMONSTRATE 
EXPANSION. 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Southern blot studies confirmed the presence of an expansion in all 20 samples 
for the CTG trinucleotide repeat found in myotonic dystrophy type 1. 
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Chapter 7. Discussion 
All patients included in this study presented with predominantly distal weakness 
and a clinical assessment of typel myotonic dystrophy was made. 
The molecular diagnosis confirmed the presence of an expanded repeat for 
myotonic dystrophy type 1 supporting the clinical diagnosis. 
The study revealed that the majority of patients referred to the Department of 
Neurology in KwaZulu - Natal who were affected by Myotonic Dystrophy were of 
Indian Descent. No patients of African origin were identified. The reasons for the 
small number of White patients may be explained by referral bias. The incidence 
of DM1 in South Africa is unknown and it is not known if a differing incidence 
exists between the Indian and White sections of the population. A previous 
study by Lotz and Van Der Meyden in 1985 identified only white patients in the 
northern Transvaal and no patients of Indian or African origin were documented. 
(io.36) G0|,-|man (37) |n ac t ion documented no South African Negroid patients 
with myotonic dystrophy. 
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In addition Goldman ( ' found that South African blacks have significantly 
fewer large repeat lengths than do white and Japanese populations and 
suggested that the occurrence of fewer large CTG repeats in the normal range 
may, in part, explain the absence of DM in Southern African blacks. 
In addition Goldman (38) suggested that DM mutations in the Afrikaans population 
might have originated from a common initial founder who introduced one of the 
European ancestral mutations. The genealogical study by Lotz and Van Der 
Meyden (10) found common ancestry amongst four of the twenty White kindreds 
studied. 
One of the limitations identified in this current study is that it evaluates a cohort 
of patients and family members referred to the Department Of Neurology. 
Patients with Myotonic Dystrophy that presented to private Neurologists would 
not have been included. As a result the actual prevalence and incidence of the 
disease could not be determined amongst the genera! population and one could 
not answer questions relating to the incidence of disease amongst the different 
racial groups. 
In this study the majority of patients demonstrated typical clinical features of 
myotonic dystrophy. EMG was diagnostic in those patients in whom they were 
performed. 
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A clinical study was performed by Lotz and Van Der Meyden w in 1980. Ninety 
six patients were identified. Seventy patients were classified as Adult Myotonic 
Dystrophy with an average age of 36.8. Eighteen patients were classified as Early 
Adult Myotonic Dystrophy with an age varying between 5 and 12 years. Eight 
patients were classified as Congenital Myotonic Dystrophy. In the current study 
we did not identify any patients with Congenital Myotonic Dystrophy or Early 
Adult Myotonic Dystrophy. The average age was similar to the average age in 
the Adult Myotonic Dystrophy subgroup of Lotz and Van Der Meydens study.(36) 
Comparison of clinical findings with those of the subgroup of Adult Myotonic 
Dystrophy from the study in South Africa by Lotz and Van Der Meyden (36) 
revealed similar findings. Mental retardation was detected in 17% of patients. 
Hypersomnolence was common but not quantified. Facial weakness was present 
in 87 % of patients. Neck flexor weakness was present in 71% of patients. Ptosis 
was noted in 40 % of patients. Extra ocular movement abnormalities were noted 
in 7% of patients. Cataracts were evaluated with bed side ophthalmoscopy and 
were present in 60% of patients. Frontal balding was common and noted in 70 
% of patients. Testicular atrophy was not documented. Wasting of the limb 
muscles was not documented but weakness was noted to be severe distally. 
Percussion induced myotonia was elicited in 90% of patients over the thenar 
eminence and in 60% of patients in the forearm muscles. 
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With regards to the severity of disease, 50 % demonstrated no or mild 
disabilities , 30 % moderate disability and 20% were wheelchair bound. Cardiac 
involvement was assessed clinically. Electrocardiography was not performed. 
Seven (10%) patients demonstrated clinical cardiac involvement. Two patients 
were known with cardiac pacemakers , two with right sided cardiac failure and 
three with extrasystoles.No laboratory,electrophysiological or molecular 
investigations were performed. Figure 6.27 A and B demonstrates the 
comparison between the two studies. 
FIGURE 6.27. A. COMPARISON OF LOTZ ET AL STUDY AND CURRENT 
STUDY 
& 4? -<# MS^ MS^ <&* & A& X? ^ ^ ^ ^ 
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FIGURE 6.27. B. COMPARISON OF LOTZ ET AL STUDY AND CURRENT 
STUDY 
With regards molecular diagnosis in the current study, PCR did not demonstrate 
any expanded repeats. However the expansions were observed in all samples 
with southern blotting. While the southern blot expansions could not be 
quantified, they usually demonstrate expanded repeats when larger than 
200.The negative PCR would therefore confirm that PCR can only be used to 
demonstrate expansions in patients with shorter repeats of between 5 - 200. 
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All patients demonstrated clinical features typical of myotonic dystrophy type 1. 
The molecular findings demonstrated markedly expanded trinucleotide repeat 
expansions which could only be confirmed on southern blotting. PCR should 
therefore be used as a screening procedure and not as a definitive diagnostic 
tool. 
Mildly symptomatic patients can also be screened with PCR, as they may possess 
shorter repeats. Further limitations in our study included our inability to quantify 
the expansion size and as a result we were unable to correlate clinical severity 
with expansion size. A possible focus in future studies would be to quantify 
expansions and correlate with the clinical severity and to assess trinucleotide 
expansions in other tissues which would aid in explaining the different disease 
profiles in different patients. 
In conclusion, this study identified patients presenting with myotonic dystrophy 
to the Department of Neurology in KwaZulu -Natal and demonstrated that 
Myotonic Dystrophy Type 1 remains the commonest clinical and molecular 
presentation. 
In addition it supported previous findings in which no South African of African 
descent was found to be affected by the disease. 
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The molecular studies confirm that PCR is of limited value as only small repeat 
expansions of less than 200 trinucleotide repeat sequences can be demonstrated 
by this method. PCR may be important as a screening tool but cannot be relied 
on to exclude the presence of an abnormal allele. Southern Blotting remains the 
gold standard in obtaining a molecular diagnosis. This is an important issue in 
the genetic counseling of patients and their families. 
Another important finding is that the clinical diagnosis was confirmed by 
molecular tests and this would suggest that clinical diagnosis is sufficient and 
molecular confirmation is not a requirement. The molecular testing would be of 
value in differentiating between DM1 and DM2 and in prenatal testing. 
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9. APPENDICES 
9.1. Appendix 1: INFORMATION DOCUMENT 
Study title: Myotonic Dystrophy : the clinical and molecular spectrum in 
Kwa Zulu Natal ref H042/06 
Dear Patient 
You have been diagnosed previously by the Department of Neurology with 
Myotonic Dystrophy. This is a muscle disorder that is inherited and may involve 
other systems in your body. The consulting neurologist, based on your clinical 
presentation and neurophysiological tests, made this diagnosis. 
I am a doctor in the Department of Neurology. I would like to invite you to 
participate in our study, which I will be using for my Masters in 
Medicine Thesis. 
Our study aims to describe the clinical and molecular features of Myotonic 
Dystrophy in KwaZulu - Natal. If you agree to participate in this study we will 
examine you during your routine follow up visit at the neuromuscular clinic. We 
will extract data regarding your age, sex, and history of illness, clinical symptoms 
and signs. 
The blood, radiological (X-rays) and neurophysiological (muscle test) 
investigations will be extracted from your previous charts. The results of the 
83 
genetic testing, which were previously performed at our local laboratory and the 
laboratory in India, will also be extracted from your charts. You will not be 
expected to increase your visits to the hospital. Your diagnosis and management 
will not be affected in any way. 
The study will help us to improve the clinical and genetic diagnosis of Myotonic 
dystrophy in our local population. Your participation is voluntary and refusal to 
participate will have no penalty in your future follow up and management. 
Personal Information will be confidential. Absolute confidentiality cannot 
be guaranteed. Personal information may be disclosed if required by law. 
Organizations that may inspect and/or copy your research records for quality 
assurance and data analysis include groups such as the Research Ethics 
Committee. 
You can contact me for further information. 
Dr Ayesha Motala 
Department of Neurology 
Tel: 031 240 2359 (secretary) 
Tel: 031 240 1991 (office) 
Cell : 0829085173 
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9.2. Appendix 2: CONSENT DOCUMENT 
Study title: Myotonic Dystrophy: clinical and molecular spectrum in 
KwaZulu- Natal 
Consent to Participate in Research 
You have been asked to participate in a research study. You have been informed 
about the study by Dr A Motala. You may contact Dr Ayesha Motala at 031 240 
2359 at any time if you have questions about the research .You may also contact 
the Medical Research Administration Office at the Nelson R Mandela School of 
Medicine at 031-260 4769 if you have any questions about your rights as a 
research participant. 
Your participation in this research is voluntary, and you will not be penalized or 
lose benefits if you refuse to participate. 
If you agree to participate, you will be given a signed copy of this document and 
the participant information sheet that is a written summary of the research. 
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The research study, including the above information, has been 
described to me verbally. I understand what my involvement in the 
study means and I voluntarily agree to participate. 
Signature of Participant Date 
Signature of Witness Date 
(Where applicable) 
Signature of Translator Date 
(Where applicable) 
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9.3. Appendix 3 MYOTONIC DYSTROPHY DATA SHEET 
MYOTONIC DYSTROPHY DATA SHEET 
1. Demographic details 
2. History 










Unaffected Not available 




Frontal Balding N 
Testicular Atrophy N 
Neurological Examination 
(A) Mental State 
1. MMSE score 
2. General comment 
3. Hypersomnolence Y N 
(B) Cranial Nerves 
Abnormal Normal 
2. VA Left Right 





Fundi Abnormal Normal 
If abnormal 
3.4.6. Abnormal Normal 
ptosis Y N 
if Y 
5. wasting of temporalis 








7. wasting of facial muscles Y N 
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weakness Y N 
8. 
Abnormal Normal 
9. dysphagia Y N 









(C) Motor System 

























Forearm extensor group 
Thenar muscles 





























































































Walks with walking aid 





4. Blood glucose 
5. CPM 
6. Creatine kinase 
7. Other 
8. Chest XRay Normal Abnormal 
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If abnormal 
9. Electrocardiograph Normal Abnormal 
If abnormal 
10. Nerve conduction studies Normal Abnormal 
If abnormal 
ll.EMG 
Myopathy 
Myotonia 
Y 
Y 
N 
N 
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